1.Gefitinib failed to show superiority to placebo as second- or third-line treatment, but it has been shown to be non inferior to docetaxel.
吉非替尼在二线和三线治疗中与安慰剂相比无优势，但其作用不逊于多西他赛。
2.Docetaxel is a chemotherapeutic drug which has recently demonstrated high efficacy in the treatment of a wide variety of tumors.
多西紫杉醇是一种化疗药物，最近还证明在一个多种肿瘤的治疗疗效高。
3.The overall response rate (ORR) tended to be higher with both weekly nab-paclitaxel regimens than docetaxel by independent radiology review.
通过独立的放射学复查，蛋白结合型紫杉醇单周方案的总有效率（ORR）要比紫杉醇高。
4.Methods: Docetaxel liposomes were prepared by modified film dispersion-high pressure homogenization and lyophilization.
方法：采用改良薄膜分散法结合冷冻干燥工艺制备多西他赛脂质体冻干粉；
5.Finally, they tested the approach in mice with an ovarian cancer cell line known to be resistant to taxane-based drugs such as docetaxel.
最后，他们检测了对紫衫烷为基础的药物如紫杉萜抵抗的卵巢癌细胞系的小鼠。
6.ABSTRACT: Objective To optimize the preparation and formulation of docetaxel-containing liposome.
摘要：目的优化制备多西紫杉醇脂质体的工艺和处方。
7.Use abiraterone for patients with castrate -resistant metastatic prostate cancer who have failed docetaxel (Taxotere).
使用阿比特龙治疗既往接受过多烯紫杉醇（泰素帝）化疗的去势难治性晚期（转移性）前列腺癌患者。
8.Objective To evaluate the efficacy, toxicity and safety of docetaxel and epirubicin in the treatment of advanced breast cancer.
目的观察多西他赛联合表阿霉素治疗晚期乳腺癌的临床疗效及毒副作用，并对安全性进行评估。
9.Therefore, it could be concluded that pro-mixed docetaxel micelles has the potential of clinical applications.
综合上述研究可见，多西紫杉醇前体混合胶束具有良好的应用前景。
10.Docetaxel has demonstrated superiority compared with best supportive care.
多西他赛证明效果优于最好的支持疗法。